
Cabaletta Bio, Inc. – NASDAQ:CABA
Cabaletta Bio stock price today
Cabaletta Bio stock price monthly change
Cabaletta Bio stock price quarterly change
Cabaletta Bio stock price yearly change
Cabaletta Bio key metrics
Market Cap | 112.50M |
Enterprise value | 103.34M |
P/E | -4.49 |
EV/Sales | N/A |
EV/EBITDA | -1.34 |
Price/Sales | N/A |
Price/Book | 1.72 |
PEG ratio | 0.12 |
EPS | -1.72 |
Revenue | N/A |
EBITDA | -84.63M |
Income | -76.86M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCabaletta Bio stock price history
Cabaletta Bio stock forecast
Cabaletta Bio financial statements
Jun 2023 | 0 | -14.48M | |
---|---|---|---|
Sep 2023 | 0 | -16.44M | |
Dec 2023 | 4.01M | -20.88M | -520.85% |
Mar 2024 | 0 | -25.04M |
Sep 2025 | 0 | -32.36M | |
---|---|---|---|
Oct 2025 | 0 | -33.40M | |
Dec 2025 | 0 | -29.95M | |
Mar 2026 | 0 | -32.18M |
Analysts Price target
Financials & Ratios estimates
Payout ratio | 0% |
---|
2019 | 3.01% |
---|---|
2020 | |
2021 | |
2022 | |
2023 |
Jun 2023 | 184637000 | 10.49M | 5.68% |
---|---|---|---|
Sep 2023 | 173287000 | 12.36M | 7.13% |
Dec 2023 | 253650000 | 17.45M | 6.88% |
Mar 2024 | 240457000 | 18.73M | 7.79% |
Jun 2023 | -11.88M | -48.14M | 94.25M |
---|---|---|---|
Sep 2023 | -12.60M | -65K | 98K |
Dec 2023 | -16.44M | 1.13M | 93.04M |
Mar 2024 | -23.98M | -812K | 6.85M |
Cabaletta Bio alternative data
Aug 2023 | 66 |
---|---|
Sep 2023 | 77 |
Oct 2023 | 77 |
Nov 2023 | 77 |
Dec 2023 | 92 |
Jan 2024 | 92 |
Feb 2024 | 92 |
Mar 2024 | 101 |
Apr 2024 | 101 |
May 2024 | 101 |
Jun 2024 | 118 |
Jul 2024 | 118 |
Cabaletta Bio other data
Period | Buy | Sel |
---|---|---|
May 2023 | 0 | 22000 |
Jun 2023 | 0 | 11000 |
Jul 2023 | 0 | 11000 |
Aug 2023 | 0 | 11000 |
Sep 2023 | 0 | 11000 |
Oct 2023 | 0 | 11000 |
Nov 2023 | 0 | 11000 |
Dec 2023 | 0 | 11000 |
Jan 2024 | 0 | 11000 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | BINDER GWENDOLYN officer: See Rema.. | Stock Option (Right to Buy) | 11,000 | $1.01 | $11,110 | ||
Option | BINDER GWENDOLYN officer: See Rema.. | Common Stock | 11,000 | $1.01 | $11,110 | ||
Sale | BINDER GWENDOLYN officer: See Rema.. | Common Stock | 10,300 | $19.54 | $201,211 | ||
Sale | BINDER GWENDOLYN officer: See Rema.. | Common Stock | 700 | $20.33 | $14,229 | ||
Option | BINDER GWENDOLYN officer: See Rema.. | Stock Option (Right to Buy) | 11,000 | $1.01 | $11,110 | ||
Option | BINDER GWENDOLYN officer: See Rema.. | Common Stock | 11,000 | $1.01 | $11,110 | ||
Sale | BINDER GWENDOLYN officer: See Rema.. | Common Stock | 7,868 | $21.76 | $171,200 | ||
Sale | BINDER GWENDOLYN officer: See Rema.. | Common Stock | 3,132 | $22.22 | $69,593 | ||
Option | BINDER GWENDOLYN officer: See Rema.. | Stock Option (Right to Buy) | 11,000 | $1.01 | $11,110 | ||
Option | BINDER GWENDOLYN officer: See Rema.. | Common Stock | 11,000 | $1.01 | $11,110 |
Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market
Cabaletta Bio: Finding Optimism In Dire Straits
Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward
Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology
Buy Cabaletta Bio's Promising SLE Treatment
Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?
Cabaletta Bio: Speculative Biotech With Opportunity
Autolus: Investment Case Further Entrenched With Latest Interim FELIX Data
-
What's the price of Cabaletta Bio stock today?
One share of Cabaletta Bio stock can currently be purchased for approximately $1.65.
-
When is Cabaletta Bio's next earnings date?
Unfortunately, Cabaletta Bio's (CABA) next earnings date is currently unknown.
-
Does Cabaletta Bio pay dividends?
No, Cabaletta Bio does not pay dividends.
-
How much money does Cabaletta Bio make?
Cabaletta Bio has a market capitalization of 112.50M.
-
What is Cabaletta Bio's stock symbol?
Cabaletta Bio, Inc. is traded on the NASDAQ under the ticker symbol "CABA".
-
What is Cabaletta Bio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cabaletta Bio?
Shares of Cabaletta Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cabaletta Bio's key executives?
Cabaletta Bio's management team includes the following people:
- Dr. Steven A. Nichtberger Co-Founder, Chairman, Chief Executive Officer & Pres(age: 64, pay: $871,160)
- Dr. David J. Chang M.D., M.P.H. Chief Medical Officer(age: 62, pay: $638,630)
- Dr. Gwendolyn K. Binder Executive Vice President of Science & Technology(age: 50, pay: $625,130)
-
Is Cabaletta Bio founder-led company?
Yes, Cabaletta Bio is a company led by its founder Dr. Steven A. Nichtberger.
-
How many employees does Cabaletta Bio have?
As Jul 2024, Cabaletta Bio employs 118 workers, which is 17% more then previous quarter.
-
When Cabaletta Bio went public?
Cabaletta Bio, Inc. is publicly traded company for more then 5 years since IPO on 25 Oct 2019.
-
What is Cabaletta Bio's official website?
The official website for Cabaletta Bio is cabalettabio.com.
-
Where are Cabaletta Bio's headquarters?
Cabaletta Bio is headquartered at 2929 Arch Street, Philadelphia, PA.
-
How can i contact Cabaletta Bio?
Cabaletta Bio's mailing address is 2929 Arch Street, Philadelphia, PA and company can be reached via phone at +267 7593100.
Cabaletta Bio company profile:

Cabaletta Bio, Inc.
cabalettabio.comNASDAQ
136
Biotechnology
Healthcare
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Philadelphia, PA 19104
CIK: 0001759138
ISIN: US12674W1099
CUSIP: 12674W109